Amputation free survival (AFS)
Fig 2 · Panel Top_panel
Panel Top_panel 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Andrew W Bradbury, Jack A Hall, Matthew A Popplewell, Lewis Meecham, Gareth R Bate, Lisa Kelly, Jon J Deeks, Catherine A Moakes, BASIL-3 Investigators
BMJ 388 e080881
OBJECTIVE: To determine which primary endovascular revascularisation strategy represents the most clinically effective treatment for patients with chronic limb threatening ischaemia who require endovascular femoro-popliteal, with or without infra-popliteal, revascularisation. DESIGN: Three arm, open label, pragmatic, multicentre, randomised, phase 3 superiority trial (BASIL-3). SETTING: 35 UK NHS vascular units. PARTICIPANTS: Patients with chronic limb threatening ischaemia who required endovascular femoro-popliteal, with or without infra-popliteal, revascularisation. INTERVENTIONS: Participants were randomly assigned (1:1:1) to femoro-popliteal plain balloon angioplasty with or without bare metal stenting (PBA±BMS), drug coated balloon angioplasty with or without bare metal stenting (DCBA±BMS), or drug eluting stenting (DES) as their first revascularisation strategy. MAIN OUTCOME MEASURES: The primary outcome was amputation free survival defined as time to first major amputation or death from any cause. Secondary outcomes included the composite components of the primary outcome, major adverse limb events, major adverse cardiac events, and other prespecified clinical and patient reported outcome measures. Serious adverse events were collected up to 30 days after the first revascularisation procedure. RESULTS: Between 29 January 2016 and 31 August 2021, 481 participants were randomised (167 (35%) women, mean age 71.8 years (standard deviation 10.8)). Major amputation or death occurred in 106 of 160 (66%) participants in the PBA±BMS group, 97 of 161 (60%) in the DCBA±BMS group, and 93 of 159 (58%) in the DES group (adjusted hazard ratios: PBA±BMS v DCBA±BMS: 0.84, 97.5% confidence interval 0.61 to 1.16, P=0.22; PBA±BMS v DES: 0.83, 0.60 to 1.15, P=0.20). No differences in serious adverse events were reported between the groups. CONCLUSIONS: Neither DCBA±BMS nor DES conferred significant clinical benefit over PBA±BMS in the femoro-popliteal segment in patients with chronic limb threatening ischaemia undergoing endovascular femoro-popliteal, with or without infra-popliteal, revascularisation. TRIAL REGISTRATION: ISRCTN registry ISRCTN14469736.
1 个 Figure · 2 个 KM 面板
Fig 2 Amputation free survival (AFS) Kaplan-Meier plot and hazard ratio over time fitted assuming non-proportional hazards (intention-to-treat analysis). CI=confidence interval
Fig 2 · Panel Top_panel
Panel Top_panel 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig 2 · Panel Bottom_panel
Panel Bottom_panel 是同一 Fig 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。